TOMASINI P.
- Country
- France
- Department
- Medical Oncology Department
Research Overview
- Phase 1/2 Open‑Label Study of VS‑7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and Combination Therapy in Patients with Advanced KRAS G12D‑Mutant Solid Tumors
- Phase 1/2 Open‑Label Study of RAS(ON) Inhibitor RMC-6291 with ivonescimab ± combination therapy in patients with advanced RAS‑mutated solid tumors
- Phase 1/2 Study of BMS-986466 with Adagrasib ± Cetuximab in KRAS G12C-Mutant Advanced Solid Tumors
Data & Insights
Has run more than one trial at 64 of 155 partner sites.
Specializations
Targeted Lung Cancer Therapies
The investigator specializes in treating non-small cell lung cancer (NSCLC) with particular focus on tumors harboring specific genetic alterations.
- EGFR mutations and targeted treatments
- ROS1 positive lung cancers
- KRAS G12C mutated tumors
Research includes novel therapeutic approaches for both locally advanced and metastatic disease stages.
Precision Medicine Applications
Focus on developing personalized treatment strategies based on specific molecular profiles and biomarkers.
- MET alterations and targeted therapies
- HER2 mutations in lung cancer
- ALK-positive tumor treatments
Investigation of innovative therapeutic combinations for treatment-resistant cases.
Advanced Treatment Modalities
Expertise in evaluating novel therapeutic approaches for complex lung cancer cases.
- Combination therapy strategies
- Bispecific antibodies development
- Treatment resistance mechanisms
Implementation of innovative therapeutic strategies for previously treated lung cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.